Upload
essien
View
41
Download
0
Tags:
Embed Size (px)
DESCRIPTION
AD-4/ACE Status Report CERN, 21 th November 2006 Niels Bassler Dept. Clinical Experimental Oncology, Aarhus University Hospital and Deutsches Krebsforschungszenrum, Heidelberg. Radiotherapy. The Quest: Hit the tumour, save the surrounding tissue!. PROTON THERAPY. PROTON THERAPY. x-rays. - PowerPoint PPT Presentation
Citation preview
AD-4/ACE Status ReportCERN, 21th November 2006
Niels Bassler
Dept. Clinical Experimental Oncology, Aarhus University Hospitaland
Deutsches Krebsforschungszenrum, Heidelberg
2
Radiotherapy
The Quest:
Hit the tumour, save the surrounding tissue!
3
PROTON THERAPY
4
PROTON THERAPYx-rays
protons
5
PROTON THERAPYx-rays
protons
6
IMRT vs. IMPT Treatment Plans
(Weber et al.)
x-rays protons
7
IMRT vs. IMPT vs. IMAT Treatment Plans
(Weber et al.)
x-rays protons
8
ANTIPROTON THERAPY ?
9
ANTIPROTONS
(FLUKA Calculation)
The idea ...
10
Antiproton Annihilation
Energy from annihilation : 2x mp ~ 1.88 GeV
Most of the energy is carried away by pions and gammas. Recoiling nuclei do the local damage, “only” about 30 MeV
pions Gamma-rays
neutronsNuclei (fragments)
11
GAFChromic Film Irradiation
Antiprotons (3 different energies)CERN – 2003
Protons (3 different energies)ASTRID, Århus, DK.
12
Radiobiology
Dose is not everything!
There is also Radiobiology:
High-LET radiation do more cell damage for the same physical dose -> higher Relative Biological Efficiency (RBE)
Due to the high LET behaviour in the antiproton peak it is not sufficient to consider physical dose alone, when doing the treatment plan.
RBE must be modeled in the treatment plan as well, since it depends on particle type, energy, tissue type etc..
13
Therefore the Radiobiology of the Antiproton beam was investigated at CERN:
14
The AD4/ACE Experiment at CERN
SCINTILLATOR (1 of 2)
CCD CAMERA
BEAM CURRENT MONITORWATER PHANTOM
TARGETBEAM
DEGRADER
15
AD4/ACE - The Test Tube
Chinese V79 Hamster Cells suspended in gelatine solution.
Cooled to a few °C to stop cell repairing.
After irradiation, slices of 0.5-1 mm are plated on Petri-dishes, and the colonies are counted.
17
CERN Results
(CERN data from 2003)
18
Relative Biological Efficiency (RBE)
Usually one would then measure the RBE (in the plateau and the peak) for antiprotons..
BUT : it is not possible to determine the RBE if the physical dose is unknown !Antiprotons have a mixed particle field, difficult to measure.(Ionization chambers were thought to be unusable...)RBE =
DCo60
DPBarsfor iso-effect
19
Relative Biological Efficiency (RBE)
Usually one would then measure the RBE (in the plateau and the peak) for antiprotons..
BUT : it is not possible to determine the RBE if the physical dose is unknown !Antiprotons have a mixed particle field, difficult to measure.(Ionization chambers were thought to be unusable...)RBE =
DCo60
DPBars
?for iso-effect
20
Biological Effective Dose Ratio (BEDR)
BiologyPhysics
( F : physical dose ratio between peak and plateau. )
BEDR : New parameter which can be measured.
BEDR describes dose ratio for peak/plateau for iso-effect.
(Any number proportional to the fluence)
(CERN data from 2003)
21
Biological Effective Dose Ratio (BEDR)
BEDR for antiprotons : ~ 9.8
BEDR for protons (TRIUMF) : ~ 2.5
=> antiprotons may be 9.8/2.5 ~ 4 times more effective in reducing the the damage to normal tissue for the same peak dose, relative to a similar degraded proton beam...
=> antiprotons may be 9.8/2.5 ~ 4 times more effective in reducing the the damage to normal tissue for the same peak dose, relative to a similar degraded proton beam...
22
Biological Effective Dose Ratio (BEDR)
BEDR for antiprotons : ~ 9.8
BEDR for protons (TRIUMF) : ~ 2.5
=> antiprotons may be 9.8/2.5 ~ 4 times more effective in reducing the the damage to normal tissue for the same peak dose, relative to a similar degraded proton beam...
=> antiprotons may be 9.8/2.5 ~ 4 times more effective in reducing the the damage to normal tissue for the same peak dose, relative to a similar degraded proton beam...
Findings were recently published in “Radiotherapy and Oncology”
Radiother Oncol (2006), doi:10.1016/j.radonc.2006.09.012
23
ANTIPROTON DOSIMETRY
BEDR is nice, but sooner or later the RBE must be measured.
Therefore dosimetry in the annihilation peak is inevitable.
Dosimetry in the plateau is easier, since antiprotons behave as protons at high velocities.
24
ANTIPROTON DOSIMETRY
Purpose: 1) Estimate dose in peak region
2) If possible derive information about particle spectrum in annihilation peak
3) Estimate peripheral damage (neutrons)
IN ANNIHILATION VERTEX: Thermoluminescent Detectors
(TLD) Alanine GAFChromic Film
IN PERIPHERAL REGION: Thermoluminescent Detectors
(TLD) Neutron Bubble Detectors
25
ANTIPROTON DOSIMETRY
IN ANNIHILATION VERTEX: Thermoluminescent Detectors
(TLD) Alanine GAFChromic Film
IN PERIPHERAL REGION: Thermoluminescent Detectors
(TLD) Neutron Bubble Detectors
TLDs7LiF and 6LiF
Alanine
GAFChromic Film
Bubble detectors
26
Dosimetry
TLDs and Alanine respond highly non-linear to high-LET radiation.Response is depending on particle energy, charge, mass, fluence.And even experimental findings of efficiencies are ambiguous!
TLD – entire signal Alanine
28
Dosimetry – Detector Efficiency Models
A track structure model (by Hansen et al.) were used for estimating Alanine response.
For estimating the TLD response in the antiproton beam the ECLaT model (based on the Local Effect Model) was applied.
Track structure models can possibly be applied to GAFChromic Films as well.
The Local Effect Model (LEM) is being used by GSI and DKFZ to predict RBEs of various cell lines in mixed particle field from Carbon ion beams with some success.
29
Comparison of Calculations and Measurements
New results from CERN - 2003 & 2004 run.
30
Comparison of Calculations and Measurements
New results from CERN - 2003 & 2004 run.
31
Peripheral Results
With TLDs the contribution from gammas, protons and pions were measured, as well as thermal neutrons.
Results (here shown per 10^7 pbars) indicate similar dose contribution as seen with proton therapy using a passive degrader.
New results from CERN - 2003 & 2004 run.
32
The central question we now want to have answered is:
What clinical results could be expected from antiproton therapy based on these observations?
Currently, the only way to give a proper answer to this question is to perform planning studies for several real cases with Antiprotons and compare with that of X-rays, protons and carbon ions.
For implementing antiprotons in a treatment planning system (TPS), exact knowledge of the dose and biology of the antiproton beam is vital.
This is happening at the DKFZ – the “TRiP98” TPS is going to be modified. Unlike conventional proton treatment planning software, TRiP includes a biology model (LEM).
Simultaneously, GEANT with the biological module is investigated.
33
OCTOBER 2006 EXPERIMENTSStatus
34
October 2006 – New Experiments
Main feature this year:
Increased energy - 125 MeV instead of 46 MeV as in 2003/2004. => larger penetration depth (~10 cm instead of ~2 cm)
1) more precise study of the effects from inflight annihilation (!)
2) better seperation of peak/plateau
3) more energy straggling => natural increased width of peak
4) possibility of generating a 1 cm SOBP
35
October 2006 – New Experiments
DOSIMETRY
primarily addressing the in-flight annihilation question
Ionization chamber measurements
Two Alanine stacks irradiated
GAFChromic Film Irradiation (HS + EBT)
BIOLOGY
Survival Curves (Clonogenic assay)
>New< : Genetic expression experiment
36
Ionization chamber measurement in water target.
Earlier thought to be impossible
Boag's two-voltage method applied to correct for general recombination. (eff. corr 1-0.8 !)
37
Oct. 2006 - Results of Ionization Chamber Measurements
Data presented here are relative. Calibration of chamber scheduled within next weeks.
38
Oct. 2006 - Results of Ionizationchamber Measurements
Comparison with FLUKA and SHIELD-HIT MC code.
SHIELD-HIT v. 2.2
Slight overestimation of peak dose.
Presumably underestimation of inflight annihilation.
39
Oct. 2006 - Results of Ionizationchamber Measurements
FLUKA 2006.3
Success! Very satisfying result!
40
Oct. 2006 - Alanine Irradiation
Alternative dosimeter, in case of ionization chamber failed.
Test of response model and particle spectrum from particle annihilation.
Dose -> Response calculation not yet performed. (will use Johnny model)
41
Oct. 2006 - GAFChromic Film Irradiation
Films are not analyzed yet.
An alternative dosimeter with different LET response.
Additional dose verification, (and on site beam verification)
42
Oct. 2006 – Biology BEDR/RBE Measurements
Analysis in progress, as dose delivered is not yet known.
PRISTINE SOBP
(MAASTRO, University of Maastricht)
43
Oct. 2006 – Biology Gene Expression Experiment
Genetic expression study of a human cell line (FaDu)
SOBP used (clinical relevance)
Slices from the Bragg-peak and a slice from the plateau have been prepared.
Qualititive experiment (understand why is RBE higher)
(Dept. of Clinical Oncology at the University Hospital in Aarhus.)
44
Summary
Antiprotons seem ~4 times more effective delivering the dose in the peak region than protons or in other words: normal tissue dose could be reduced ~4 times for the same target dose.
FLUKA was benchmarked and will most likely be the preferred choice for Monte Carlo simulation of Antiproton annihilation.
This dataset will be used for implementing antiprotons in treatment planning system, and benchmarking it.
45
Outlook
RBEs can very soon be extracted, based on experimentally verified MC simulations.
Heavy-ion treatment planning system TRiP from DKFZ/GSI will be modified to support antiprotons.
Further investigation of the far peripheral damage – (stochastic effects.)
Further investigation of the biological effect in the immediate surrounding of the beam (i.e. “the tail”).
We will then be able to evaluate the clinical potential of antiproton therapy.